Loading…
Total Plasma Sulfide in Congestive Heart Failure
Abstract Background Hydrogen sulfide (H2 S) has emerged as a third gaseous transmitter in mammals. In animal models of heart failure, treatment with an H2 S donor can protect the heart against adverse remodeling and attenuate cardiac dysfunction. The aim was to determine total plasma sulfide in pati...
Saved in:
Published in: | Journal of cardiac failure 2012-07, Vol.18 (7), p.541-548 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c423t-46d3202e5f65d631ce3a0011a1986f8ac4a33b43e80210d479f47b7a9ebe0bd93 |
---|---|
cites | cdi_FETCH-LOGICAL-c423t-46d3202e5f65d631ce3a0011a1986f8ac4a33b43e80210d479f47b7a9ebe0bd93 |
container_end_page | 548 |
container_issue | 7 |
container_start_page | 541 |
container_title | Journal of cardiac failure |
container_volume | 18 |
creator | Kovačić, Dragan, MD, PhD Glavnik, Nina, MD Marinšek, Matej, MD Zagožen, Petra, MD Rovan, Ksenija, MD Goslar, Tomaž, MD Marš, Tomaž, MD, PhD Podbregar, Matej, MD, PhD |
description | Abstract Background Hydrogen sulfide (H2 S) has emerged as a third gaseous transmitter in mammals. In animal models of heart failure, treatment with an H2 S donor can protect the heart against adverse remodeling and attenuate cardiac dysfunction. The aim was to determine total plasma sulfide in patients with congestive heart failure. Methods and Results Total plasma sulfide was determined in 57 patients on admission to an outpatient clinic or cardiology department. Total plasma sulfide concentrations in these patients was lower compared with a control group (5.32 [2.22, 8.00] μM vs. 8.5 [6.00, 14.00] μM; P = .05). Total plasma sulfide decreased significantly across the New York Heart Association (NYHA) functional classes (II, 5.84 [4.33, 8.00] μM vs. III, 4.67 [4.00, 7.17] μM vs. IV, 2.67 [2.22, 4.31] μM; P = .001). The total plasma sulfide negatively correlated with pro-BNP (R2 cubic, 0.692; P = .001) and pulmonary artery systolic pressure (R2 cubic, 0.569; P = .001). The receiver operating characteristic analysis of the area under the curve for total plasma sulfide as a predictor of mortality was 0.904 (95% CI, 0.822–0.987; P = .001), and of rehospitalization was 0.779 (95% CI, 0.650–0.908; P = .001). Total plasma sulfide was a univariate predictor of mortality (odds ratio, 0.245; 95% CI, 0.108–0.555; P = .001). Conclusion Total plasma sulfide is negatively related to severity of congestive heart failure: it is lowest in NYHA Class IV and in patients with high pro-BNP and high pulmonary artery pressure. Low total plasma sulfide predicts a higher mortality rate. |
doi_str_mv | 10.1016/j.cardfail.2012.04.011 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1023292182</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1071916412001509</els_id><sourcerecordid>1023292182</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-46d3202e5f65d631ce3a0011a1986f8ac4a33b43e80210d479f47b7a9ebe0bd93</originalsourceid><addsrcrecordid>eNqFkTtPxDAQhC0E4v0XUEqahF3bl0eDQCdeEhJIQG059gb58CVgJyfx7_HpgIKGyi5mdma_ZewEoUDA8mxRGB1sp50vOCAvQBaAuMX2cSZ4XkuU2-kPFeYNlnKPHcS4AIBaQrXL9jivZC3rap_B8zBqnz16HZc6e5p85yxlrs_mQ_9KcXQrym5JhzG7TllToCO202kf6fj7PWQv11fP89v8_uHmbn55nxvJxZjL0goOnGZdObOlQENCQ2qosanLrtZGaiFaKagGjmBl1XSyaivdUEvQ2kYcstPN3PcwfEypiVq6aMh73dMwRYXABW841jxJy43UhCHGQJ16D26pw2cSqTUttVA_tNSalgKpUpdkPPnOmNol2V_bD54kuNgIKG26chRUNI56Q9YFMqOyg_s_4_zPCONd74z2b_RJcTFMoU8cFaqYPOppfbP1yZAnXDNoxBfHIpEd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1023292182</pqid></control><display><type>article</type><title>Total Plasma Sulfide in Congestive Heart Failure</title><source>ScienceDirect Freedom Collection</source><creator>Kovačić, Dragan, MD, PhD ; Glavnik, Nina, MD ; Marinšek, Matej, MD ; Zagožen, Petra, MD ; Rovan, Ksenija, MD ; Goslar, Tomaž, MD ; Marš, Tomaž, MD, PhD ; Podbregar, Matej, MD, PhD</creator><creatorcontrib>Kovačić, Dragan, MD, PhD ; Glavnik, Nina, MD ; Marinšek, Matej, MD ; Zagožen, Petra, MD ; Rovan, Ksenija, MD ; Goslar, Tomaž, MD ; Marš, Tomaž, MD, PhD ; Podbregar, Matej, MD, PhD</creatorcontrib><description>Abstract Background Hydrogen sulfide (H2 S) has emerged as a third gaseous transmitter in mammals. In animal models of heart failure, treatment with an H2 S donor can protect the heart against adverse remodeling and attenuate cardiac dysfunction. The aim was to determine total plasma sulfide in patients with congestive heart failure. Methods and Results Total plasma sulfide was determined in 57 patients on admission to an outpatient clinic or cardiology department. Total plasma sulfide concentrations in these patients was lower compared with a control group (5.32 [2.22, 8.00] μM vs. 8.5 [6.00, 14.00] μM; P = .05). Total plasma sulfide decreased significantly across the New York Heart Association (NYHA) functional classes (II, 5.84 [4.33, 8.00] μM vs. III, 4.67 [4.00, 7.17] μM vs. IV, 2.67 [2.22, 4.31] μM; P = .001). The total plasma sulfide negatively correlated with pro-BNP (R2 cubic, 0.692; P = .001) and pulmonary artery systolic pressure (R2 cubic, 0.569; P = .001). The receiver operating characteristic analysis of the area under the curve for total plasma sulfide as a predictor of mortality was 0.904 (95% CI, 0.822–0.987; P = .001), and of rehospitalization was 0.779 (95% CI, 0.650–0.908; P = .001). Total plasma sulfide was a univariate predictor of mortality (odds ratio, 0.245; 95% CI, 0.108–0.555; P = .001). Conclusion Total plasma sulfide is negatively related to severity of congestive heart failure: it is lowest in NYHA Class IV and in patients with high pro-BNP and high pulmonary artery pressure. Low total plasma sulfide predicts a higher mortality rate.</description><identifier>ISSN: 1071-9164</identifier><identifier>EISSN: 1532-8414</identifier><identifier>DOI: 10.1016/j.cardfail.2012.04.011</identifier><identifier>PMID: 22748487</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Blood Pressure - physiology ; Cardiovascular ; Case-Control Studies ; Congestive heart failure ; Female ; Heart Failure - blood ; Heart Failure - classification ; Heart Failure - mortality ; Humans ; Male ; Natriuretic Peptide, Brain - blood ; outcome ; Patient Readmission ; Peptide Fragments - blood ; Pulmonary Artery - physiology ; ROC Curve ; Sensitivity and Specificity ; Severity of Illness Index ; sulfide ; Sulfides - blood ; Systole - physiology</subject><ispartof>Journal of cardiac failure, 2012-07, Vol.18 (7), p.541-548</ispartof><rights>Elsevier Inc.</rights><rights>2012 Elsevier Inc.</rights><rights>Copyright © 2012 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-46d3202e5f65d631ce3a0011a1986f8ac4a33b43e80210d479f47b7a9ebe0bd93</citedby><cites>FETCH-LOGICAL-c423t-46d3202e5f65d631ce3a0011a1986f8ac4a33b43e80210d479f47b7a9ebe0bd93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22748487$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kovačić, Dragan, MD, PhD</creatorcontrib><creatorcontrib>Glavnik, Nina, MD</creatorcontrib><creatorcontrib>Marinšek, Matej, MD</creatorcontrib><creatorcontrib>Zagožen, Petra, MD</creatorcontrib><creatorcontrib>Rovan, Ksenija, MD</creatorcontrib><creatorcontrib>Goslar, Tomaž, MD</creatorcontrib><creatorcontrib>Marš, Tomaž, MD, PhD</creatorcontrib><creatorcontrib>Podbregar, Matej, MD, PhD</creatorcontrib><title>Total Plasma Sulfide in Congestive Heart Failure</title><title>Journal of cardiac failure</title><addtitle>J Card Fail</addtitle><description>Abstract Background Hydrogen sulfide (H2 S) has emerged as a third gaseous transmitter in mammals. In animal models of heart failure, treatment with an H2 S donor can protect the heart against adverse remodeling and attenuate cardiac dysfunction. The aim was to determine total plasma sulfide in patients with congestive heart failure. Methods and Results Total plasma sulfide was determined in 57 patients on admission to an outpatient clinic or cardiology department. Total plasma sulfide concentrations in these patients was lower compared with a control group (5.32 [2.22, 8.00] μM vs. 8.5 [6.00, 14.00] μM; P = .05). Total plasma sulfide decreased significantly across the New York Heart Association (NYHA) functional classes (II, 5.84 [4.33, 8.00] μM vs. III, 4.67 [4.00, 7.17] μM vs. IV, 2.67 [2.22, 4.31] μM; P = .001). The total plasma sulfide negatively correlated with pro-BNP (R2 cubic, 0.692; P = .001) and pulmonary artery systolic pressure (R2 cubic, 0.569; P = .001). The receiver operating characteristic analysis of the area under the curve for total plasma sulfide as a predictor of mortality was 0.904 (95% CI, 0.822–0.987; P = .001), and of rehospitalization was 0.779 (95% CI, 0.650–0.908; P = .001). Total plasma sulfide was a univariate predictor of mortality (odds ratio, 0.245; 95% CI, 0.108–0.555; P = .001). Conclusion Total plasma sulfide is negatively related to severity of congestive heart failure: it is lowest in NYHA Class IV and in patients with high pro-BNP and high pulmonary artery pressure. Low total plasma sulfide predicts a higher mortality rate.</description><subject>Aged</subject><subject>Blood Pressure - physiology</subject><subject>Cardiovascular</subject><subject>Case-Control Studies</subject><subject>Congestive heart failure</subject><subject>Female</subject><subject>Heart Failure - blood</subject><subject>Heart Failure - classification</subject><subject>Heart Failure - mortality</subject><subject>Humans</subject><subject>Male</subject><subject>Natriuretic Peptide, Brain - blood</subject><subject>outcome</subject><subject>Patient Readmission</subject><subject>Peptide Fragments - blood</subject><subject>Pulmonary Artery - physiology</subject><subject>ROC Curve</subject><subject>Sensitivity and Specificity</subject><subject>Severity of Illness Index</subject><subject>sulfide</subject><subject>Sulfides - blood</subject><subject>Systole - physiology</subject><issn>1071-9164</issn><issn>1532-8414</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqFkTtPxDAQhC0E4v0XUEqahF3bl0eDQCdeEhJIQG059gb58CVgJyfx7_HpgIKGyi5mdma_ZewEoUDA8mxRGB1sp50vOCAvQBaAuMX2cSZ4XkuU2-kPFeYNlnKPHcS4AIBaQrXL9jivZC3rap_B8zBqnz16HZc6e5p85yxlrs_mQ_9KcXQrym5JhzG7TllToCO202kf6fj7PWQv11fP89v8_uHmbn55nxvJxZjL0goOnGZdObOlQENCQ2qosanLrtZGaiFaKagGjmBl1XSyaivdUEvQ2kYcstPN3PcwfEypiVq6aMh73dMwRYXABW841jxJy43UhCHGQJ16D26pw2cSqTUttVA_tNSalgKpUpdkPPnOmNol2V_bD54kuNgIKG26chRUNI56Q9YFMqOyg_s_4_zPCONd74z2b_RJcTFMoU8cFaqYPOppfbP1yZAnXDNoxBfHIpEd</recordid><startdate>20120701</startdate><enddate>20120701</enddate><creator>Kovačić, Dragan, MD, PhD</creator><creator>Glavnik, Nina, MD</creator><creator>Marinšek, Matej, MD</creator><creator>Zagožen, Petra, MD</creator><creator>Rovan, Ksenija, MD</creator><creator>Goslar, Tomaž, MD</creator><creator>Marš, Tomaž, MD, PhD</creator><creator>Podbregar, Matej, MD, PhD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120701</creationdate><title>Total Plasma Sulfide in Congestive Heart Failure</title><author>Kovačić, Dragan, MD, PhD ; Glavnik, Nina, MD ; Marinšek, Matej, MD ; Zagožen, Petra, MD ; Rovan, Ksenija, MD ; Goslar, Tomaž, MD ; Marš, Tomaž, MD, PhD ; Podbregar, Matej, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-46d3202e5f65d631ce3a0011a1986f8ac4a33b43e80210d479f47b7a9ebe0bd93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Blood Pressure - physiology</topic><topic>Cardiovascular</topic><topic>Case-Control Studies</topic><topic>Congestive heart failure</topic><topic>Female</topic><topic>Heart Failure - blood</topic><topic>Heart Failure - classification</topic><topic>Heart Failure - mortality</topic><topic>Humans</topic><topic>Male</topic><topic>Natriuretic Peptide, Brain - blood</topic><topic>outcome</topic><topic>Patient Readmission</topic><topic>Peptide Fragments - blood</topic><topic>Pulmonary Artery - physiology</topic><topic>ROC Curve</topic><topic>Sensitivity and Specificity</topic><topic>Severity of Illness Index</topic><topic>sulfide</topic><topic>Sulfides - blood</topic><topic>Systole - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kovačić, Dragan, MD, PhD</creatorcontrib><creatorcontrib>Glavnik, Nina, MD</creatorcontrib><creatorcontrib>Marinšek, Matej, MD</creatorcontrib><creatorcontrib>Zagožen, Petra, MD</creatorcontrib><creatorcontrib>Rovan, Ksenija, MD</creatorcontrib><creatorcontrib>Goslar, Tomaž, MD</creatorcontrib><creatorcontrib>Marš, Tomaž, MD, PhD</creatorcontrib><creatorcontrib>Podbregar, Matej, MD, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cardiac failure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kovačić, Dragan, MD, PhD</au><au>Glavnik, Nina, MD</au><au>Marinšek, Matej, MD</au><au>Zagožen, Petra, MD</au><au>Rovan, Ksenija, MD</au><au>Goslar, Tomaž, MD</au><au>Marš, Tomaž, MD, PhD</au><au>Podbregar, Matej, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Total Plasma Sulfide in Congestive Heart Failure</atitle><jtitle>Journal of cardiac failure</jtitle><addtitle>J Card Fail</addtitle><date>2012-07-01</date><risdate>2012</risdate><volume>18</volume><issue>7</issue><spage>541</spage><epage>548</epage><pages>541-548</pages><issn>1071-9164</issn><eissn>1532-8414</eissn><abstract>Abstract Background Hydrogen sulfide (H2 S) has emerged as a third gaseous transmitter in mammals. In animal models of heart failure, treatment with an H2 S donor can protect the heart against adverse remodeling and attenuate cardiac dysfunction. The aim was to determine total plasma sulfide in patients with congestive heart failure. Methods and Results Total plasma sulfide was determined in 57 patients on admission to an outpatient clinic or cardiology department. Total plasma sulfide concentrations in these patients was lower compared with a control group (5.32 [2.22, 8.00] μM vs. 8.5 [6.00, 14.00] μM; P = .05). Total plasma sulfide decreased significantly across the New York Heart Association (NYHA) functional classes (II, 5.84 [4.33, 8.00] μM vs. III, 4.67 [4.00, 7.17] μM vs. IV, 2.67 [2.22, 4.31] μM; P = .001). The total plasma sulfide negatively correlated with pro-BNP (R2 cubic, 0.692; P = .001) and pulmonary artery systolic pressure (R2 cubic, 0.569; P = .001). The receiver operating characteristic analysis of the area under the curve for total plasma sulfide as a predictor of mortality was 0.904 (95% CI, 0.822–0.987; P = .001), and of rehospitalization was 0.779 (95% CI, 0.650–0.908; P = .001). Total plasma sulfide was a univariate predictor of mortality (odds ratio, 0.245; 95% CI, 0.108–0.555; P = .001). Conclusion Total plasma sulfide is negatively related to severity of congestive heart failure: it is lowest in NYHA Class IV and in patients with high pro-BNP and high pulmonary artery pressure. Low total plasma sulfide predicts a higher mortality rate.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>22748487</pmid><doi>10.1016/j.cardfail.2012.04.011</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1071-9164 |
ispartof | Journal of cardiac failure, 2012-07, Vol.18 (7), p.541-548 |
issn | 1071-9164 1532-8414 |
language | eng |
recordid | cdi_proquest_miscellaneous_1023292182 |
source | ScienceDirect Freedom Collection |
subjects | Aged Blood Pressure - physiology Cardiovascular Case-Control Studies Congestive heart failure Female Heart Failure - blood Heart Failure - classification Heart Failure - mortality Humans Male Natriuretic Peptide, Brain - blood outcome Patient Readmission Peptide Fragments - blood Pulmonary Artery - physiology ROC Curve Sensitivity and Specificity Severity of Illness Index sulfide Sulfides - blood Systole - physiology |
title | Total Plasma Sulfide in Congestive Heart Failure |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T21%3A13%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Total%20Plasma%20Sulfide%20in%20Congestive%20Heart%20Failure&rft.jtitle=Journal%20of%20cardiac%20failure&rft.au=Kova%C4%8Di%C4%87,%20Dragan,%20MD,%20PhD&rft.date=2012-07-01&rft.volume=18&rft.issue=7&rft.spage=541&rft.epage=548&rft.pages=541-548&rft.issn=1071-9164&rft.eissn=1532-8414&rft_id=info:doi/10.1016/j.cardfail.2012.04.011&rft_dat=%3Cproquest_cross%3E1023292182%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c423t-46d3202e5f65d631ce3a0011a1986f8ac4a33b43e80210d479f47b7a9ebe0bd93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1023292182&rft_id=info:pmid/22748487&rfr_iscdi=true |